{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:49:17Z","timestamp":1783774157508,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.yebeh.2017.06.038","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T18:15:39Z","timestamp":1503166539000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression"],"prefix":"10.1016","volume":"75","author":[{"given":"Steve","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Dobrinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.06.038_bb0005","series-title":"FYCOMPA (perampanel) US Prescribing Information","year":"2017"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2017.06.038_bb9000","unstructured":"EUROPEAN MEDICINES AGENCY (EMA). Fycompa. Annex I: Summary of Product Characteristics. Available at http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002434\/human_med_001572.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.yebeh.2017.06.038_bb0015","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0035","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0040","series-title":"KEPPRA (levetiracetam) prescribing information","year":"2016"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0045","series-title":"TOPAMAX (topiramate) prescribing information","year":"2014"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0055","series-title":"Introductory guide to Standardised MedDRA Queries (SMQs)","author":"MedDRA Maintenance and Support Services Organization","year":"2012"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0060","series-title":"Standardised MedDRA Queries. MedDRA website","year":"2014"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","article-title":"Management of psychiatric and neurological comorbidities in epilepsy","volume":"12","author":"Kanner","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0075","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","article-title":"Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations","volume":"26","author":"Piedad","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.06.038_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002564","article-title":"Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register","volume":"3","author":"Wieshmann","year":"2013","journal-title":"BMJ Open"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017302585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017302585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T15:00:33Z","timestamp":1538665233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017302585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":17,"alternative-id":["S1525505017302585"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.06.038","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}